| Role of bile acids and bile acid receptors in metabolic regulation P Lefebvre, B Cariou, F Lien, F Kuipers, B Staels Physiological reviews 89 (1), 147-191, 2009 | 1879 | 2009 |
| Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study B Cariou, S Hadjadj, M Wargny, M Pichelin, A Al-Salameh, I Allix, ... Diabetologia 63 (8), 1500-1515, 2020 | 979 | 2020 |
| PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial FJ Raal, EA Stein, R Dufour, T Turner, F Civeira, L Burgess, G Langslet, ... The Lancet 385 (9965), 331-340, 2015 | 909 | 2015 |
| The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice B Cariou, K Van Harmelen, D Duran-Sandoval, TH Van Dijk, A Grefhorst, ... Journal of Biological Chemistry 281 (16), 11039-11049, 2006 | 658 | 2006 |
| Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease JF Yale, G Bakris, B Cariou, D Yue, E David‐Neto, L Xi, K Figueroa, ... Diabetes, Obesity and Metabolism 15 (5), 463-473, 2013 | 635 | 2013 |
| Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY … CP Cannon, B Cariou, D Blom, JM McKenney, C Lorenzato, R Pordy, ... European heart journal 36 (19), 1186-1194, 2015 | 501 | 2015 |
| Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic … B Staels, A Rubenstrunk, B Noel, G Rigou, P Delataille, LJ Millatt, ... Hepatology 58 (6), 1941-1952, 2013 | 469 | 2013 |
| Thiazolidinediones and PPARγ agonists: time for a reassessment B Cariou, B Charbonnel, B Staels Trends in Endocrinology & Metabolism 23 (5), 205-215, 2012 | 459 | 2012 |
| Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) B Zinman, A Philis-Tsimikas, B Cariou, Y Handelsman, HW Rodbard, ... Diabetes care 35 (12), 2464-2471, 2012 | 458 | 2012 |
| Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 … VR Aroda, SC Bain, B Cariou, M Piletič, L Rose, M Axelsen, E Rowe, ... The lancet Diabetes & endocrinology 5 (5), 355-366, 2017 | 401 | 2017 |
| PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study AF Schmidt, DI Swerdlow, MV Holmes, RS Patel, Z Fairhurst-Hunter, ... The lancet Diabetes & endocrinology 5 (2), 97-105, 2017 | 398 | 2017 |
| Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c P Costet, B Cariou, G Lambert, F Lalanne, B Lardeux, AL Jarnoux, ... Journal of Biological Chemistry 281 (10), 6211-6218, 2006 | 379 | 2006 |
| Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity J Prawitt, M Abdelkarim, JHM Stroeve, I Popescu, H Duez, VR Velagapudi, ... Diabetes 60 (7), 1861-1871, 2011 | 361 | 2011 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised … P Dandona, C Mathieu, M Phillip, L Hansen, SC Griffen, D Tschöpe, ... The lancet Diabetes & endocrinology 5 (11), 864-876, 2017 | 311 | 2017 |
| International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors T Danne, S Garg, AL Peters, JB Buse, C Mathieu, JH Pettus, ... Diabetes care 42 (6), 1147-1154, 2019 | 308 | 2019 |
| Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease JF Yale, G Bakris, B Cariou, J Nieto, E David‐Neto, D Yue, E Wajs, ... Diabetes, Obesity and Metabolism 16 (10), 1016-1027, 2014 | 294 | 2014 |
| The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition D Duran-Sandoval, B Cariou, F Percevault, N Hennuyer, A Grefhorst, ... Journal of Biological Chemistry 280 (33), 29971-29979, 2005 | 254 | 2005 |
| Dual Peroxisome Proliferator–Activated Receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects B Cariou, R Hanf, S Lambert-Porcheron, Y Zair, V Sauvinet, B Noël, L Flet, ... Diabetes care 36 (10), 2923-2930, 2013 | 249 | 2013 |
| Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial B Zinman, VR Aroda, JB Buse, B Cariou, SB Harris, ST Hoff, KB Pedersen, ... Diabetes care 42 (12), 2262-2271, 2019 | 242 | 2019 |
| Peroxisome proliferator–activated receptor α induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-α activation properties E Teissier, A Nohara, G Chinetti, R Paumelle, B Cariou, JC Fruchart, ... Circulation research 95 (12), 1174-1182, 2004 | 235 | 2004 |
